NL
NVO

NorthAvenue LLC’s Novo Nordisk NVO Stock Holding History

NorthAvenue LLC’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9K Hold
331
– – 0.01% 119
2026
Q1 		$12.2K Hold
331
– – 0.01% 118
2025
Q4 		$16.8K Buy
+331
New +$16.9K 0.01% 106

Other funds holding NVO

SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
OFA
Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
ONB
Old National Bancorp Evansville, Indiana $5.02B AUM 25.65% 1-Year Est. Return
VFM
Viking Fund Management Minot, North Dakota $1.12B AUM 44.65% 1-Year Est. Return

NorthAvenue LLC's NVO Position: Q2 2026 in Review

NorthAvenue LLC held its Novo Nordisk (NVO) position steady in Q2 2026 at 331 shares worth $15.9K. The position accounts for 0.01% of the portfolio, ranked #119.

NorthAvenue LLC first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. The position peaked at $16.8K in Q4 2025. 272 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • NorthAvenue LLC held 331 shares of Novo Nordisk worth $15.9K as of Q2 2026.
  • NorthAvenue LLC left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up 0.01% of NorthAvenue LLC's portfolio in Q2 2026, its #119 holding.
  • NorthAvenue LLC first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
  • NorthAvenue LLC's Novo Nordisk position peaked at $16.8K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on NorthAvenue LLC's 13F filing for Q2 2026, filed 21 Jul 2026.